You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The firm said it will use the funding to consolidate its position in clinical diagnostics, establish a US office, and enter new diagnostic markets.
As part of a collaboration with Freenome, Institut Curie will look for correlations between circulating biomarkers and human response to cancer immunotherapies.
The researchers said that their deep-learning interpreter of outcomes for patients with gliomas could be more accurate and objective than pathologists.
Because of a statistical error in a recent study, the firm reduced test performance numbers, but it noted that the revised numbers are still far better than standard histopathology.
The collaboration will use AI to determine if patients can be grouped based on diagnostic test information, potentially leading to quicker and better diagnoses and treatments.
The Israeli molecular diagnostics company will use artificial intelligence and phenotypic analysis to increase the diagnostic rate of its genetic tests.
The company has also developed two liquid biopsy cancer test, Liquid GPS Core for DNA and Liquid GPS Expression for RNA.
Sophia Genetics has received a CE-IVD mark for a sequencing-based test that, combined with data analytics, is meant to improve detection of leukemia.
UgenTec will develop artificially intelligent software to support interpretation of MDxHealth's ConfirMDx and SelectMDx molecular prostate cancer tests.
Funds will support projects aimed at earlier identification of patients who can benefit from treatment.